ストックスクリーナーアプリを入手
3.20
4.48%
-0.15
アフターアワーズ：
3.20
Bolt Biotherapeutics Inc (BOLT) 最新ニュース
Renaissance Technologies (BOLT) reports 5.13% ownership stake in Bolt Biotherapeutics - Stock Titan
Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
BOLT Looks 49.0% Undervalued on GF Value™ Despite Clinical-Stage Challenges - GuruFocus
Bolt Biotherapeutics Inc.: Q2 Earnings Snapshot - KVUE
Bolt Biotherapeutics Q2 net loss narrows on restructuring and lower research activity - TradingView
Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Bolt Biotherapeutics, Inc. Q2 2026: Revenue $5K, Net loss $(7.72M), EPS $(4.57) — 10-Q Summary - TradingView
Bolt Biotherapeutics (BOLT) flags going concern risk as losses fall and cash nears $18M - Stock Titan
Bolt Biotherapeutics' Cancer Trial Data Expected With Q3 Results - Stock Titan
Bolt Biotherapeutics (BOLT) Advances 4.65% as Buyers Defend Key SupportSymmetrical Triangle - dars.gov.et
Bolt Biotherapeutics Inc (BOLT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BOLT Q2'26 Earnings: revenue estimate is 500.00K USD - TradingView
Bolt Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:BOLT - TradingView
Bolt Biotherapeutics Inc (BOLT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bolt Biotherapeutics Inc (BOLT) Valuation: PE, PB & Fair Value Analysis - tradingkey.com
Bolt Biotherapeutics Inc (BOLT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
Bolt Biotherapeutics Inc (BOLT) Cash Flow - TradingKey
BOLT|Bolt Biotherapeutics Inc|Price:3.830|Chg%:+0.110 - TradingKey
Bolt Biotherapeutics Inc (BOLT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bolt Biotherapeutics Inc. (BOLT) Q1 2026 Earnings: Wider-than-Expected Loss Amid Clinical Development ProgressAnalyst Consensus Shift - dars.gov.et
Bolt Biotherapeutics Inc. (BOLT) Q1 2026 Earnings: Wider-than-Expected Loss as Development Stage Company Reports No RevenueROE Trend Analysis - dars.gov.et
Bolt Biotherapeutics (BOLT) Gains Momentum: Stock Rises 1.82% Amid Potential Biotech RallyZigzag Correction - dars.gov.et
Bolt Biotherapeutics Inc (BOLT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
A419U9 Forecast — Price Target — Prediction for 2027 - TradingView
BOLT Forecast — Price Target — Prediction for 2027 - TradingView
Bolt Biotherapeutics, Inc. Actuals & Estimates (MUN:6LP0) - TradingView
Enterprise value to revenue forward of Bolt Biotherapeutics, Inc. – NASDAQ:BOLT - TradingView
Revenue per share of Bolt Biotherapeutics, Inc. – FWB:6LP0 - TradingView
6LP0 Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Bolt Biotherapeutics, Inc. – NASDAQ:BOLT - TradingView
Bolt Biotherapeutics (BOLT) Slides 5% in Heavy Trading as Key Support Level ApproachesVOLD Alert - dars.gov.et
Bolt Biotherapeutics Inc (BOLT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bolt Biotherapeutics Inc (BOLT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bolt Biotherapeutics Inc (BOLT) Institutional Confidence - TradingKey
Bolt Biotherapeutics Inc. (BOLT) Q1 2026 Earnings: Large EPS Miss Reflects Continued R&D InvestmentEPS Growth Rate - newsline.com
Bolt Biotherapeutics Holds 2026 Annual Stockholder Meeting - TipRanks
Bolt Biotherapeutics (BOLT) director receives 5,000 stock options at $4.43 exercise price - Stock Titan
Bolt Biotherapeutics (NASDAQ: BOLT) grants director options for 5,000 shares - Stock Titan
Bolt Biotherapeutics (NASDAQ: BOLT) director receives 5,000-share stock option grant - Stock Titan
Bolt Biotherapeutics (BOLT) director receives 5,000 stock options at $4.43 strike price - Stock Titan
Bolt Biotherapeutics (BOLT) director receives 5,000 stock options at $4.43 strike - Stock Titan
Bolt Biotherapeutics (BOLT) Dips 2.33% as Biotech Sector Headwinds PersistVolatility Stop - DonanımHaber
Bolt Biotherapeutics (BOLT) Declines Over 4%, Nears Critical Support LevelFade Trade - po-news-eg.net
Bolt Biotherapeutics (BOLT) Slides 4% Amid Biotech Sector Turbulence – Key Levels to WatchDark Pool Sentiment - dars.gov.et
BOLT Q1 2026 Earnings: Deep EPS Miss Highlights Operational ChallengesPost-Earnings Drift - newsline.com
Bolt Biotherapeutics Price Target Announced at $22.00/Share by Rodman & Renshaw - Moomoo
BOLT Initiates Coverage On Rodman & Renshaw -- Rating Set to Buy - GuruFocus
Rodman & Renshaw initiates Bolt Biotherapeutics stock with buy rating By Investing.com - Investing.com Nigeria
Bolt Biotherapeutics (BOLT) Gains 2.32%: Biotech Stock Approaches Key Resistance LevelIchimoku Kumo Twist - The Legal Advocate
Rodman & Renshaw initiates Bolt Biotherapeutics stock with buy rating - Investing.com
Bolt Biotherapeutics (BOLT) Edges Higher Amid Tight Trading Range – Support and Resistance Levels in FocusWyckoff Distribution - The Legal Advocate
BOLTBolt Biotherapeutics Inc Stock Price and Quote - Finviz
Bolt Biotherapeutics Q1 2026 Earnings: Wider-Than-Expected Loss Amid Pre-Revenue StageDiluted EPS Report - newsline.com
Bolt Biotherapeutics (BOLT) Slips 1.2% as Shares Test Key Support at $4.65Breadth Thrust - The Legal Advocate
1.80%
1.77%
大文字化:
|
ボリューム (24 時間):